Stephanie Johnson, Pfizer, explains how off-platform triggers, single-owner risk registers, and traceable prior knowledge keep protein formulation programs on track.
News|Articles|November 23, 2016
Kymos Acquires Italian Firm Pharmaprogress
Author(s)Pharmaceutical Technology Editors
Spanish CRO, Kymos Pharma Services, announced that it has acquired Pharmaprogress, an Italian firm based in Ancona, specializing in contract research and analysis services.
Advertisement
Spanish CRO, Kymos Pharma Services, announced that it has acquired Pharmaprogress, an Italian firm based in Ancona, specializing in contract research and analysis services. Pharmaprogress has a 700-m2 analysis laboratory that is GMP authorized by the Italian Medicines Agency. The company is expected to deliver a turnover of EUR1 million in 2017.
Founded in 2001, Kymos has since worked on expanding internationally. With the acquisition of Pharmaprogress, Kymos estimates that 50% of its business volume will be generated outside Spain. Kymos’ main markets are Italy, France, Switzerland, Germany, and Portugal.
Source:
Advertisement
Related to this article
Stephanie Johnson, Pfizer, discusses how platform formulations moved 2 Pfizer protein programs to IND in 8 months by redistributing, not removing risk.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
How to test pen injector assembly interfaces from URS to FAT and SAT: verify part tracking, reject confirmation, restarts, and data transfer evidence.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pharma Leaders Weigh in On AI's Measurable Results In 2026
2
Manufacturing Intelligence: How AI Poisoning Hides in Plain Sight
3
Ravulizumab's IgA Nephropathy Approval Expands Large-Molecule Biologic Demand
4
Pfizer's 8-Month Path from Candidate to IND: AAPS PharmSci 360 2026
5